A Regimen Finding Study to Induce Tolerance in de Novo Renal Transplantation
Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a
human anti-CD2 antibody, combined with donor bone marrow and non-myeloablative conditioning,
for tolerance induction in de novo living donor renal transplantation.